Cargando…
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459616/ https://www.ncbi.nlm.nih.gov/pubmed/36090643 http://dx.doi.org/10.21037/tlcr-22-545 |
_version_ | 1784786553823821824 |
---|---|
author | Bian, Dongliang Jiang, Siming Xiong, Yicheng Qi, Mengfan Wu, Jiawei Addeo, Alfredo Yamauchi, Yoshikane Manapov, Farkhad Dempke, Wolfram C. M. Vannucci, Jacopo Di Federico, Alessandro Xu, Xiaoxiong Chen, Linsong |
author_facet | Bian, Dongliang Jiang, Siming Xiong, Yicheng Qi, Mengfan Wu, Jiawei Addeo, Alfredo Yamauchi, Yoshikane Manapov, Farkhad Dempke, Wolfram C. M. Vannucci, Jacopo Di Federico, Alessandro Xu, Xiaoxiong Chen, Linsong |
author_sort | Bian, Dongliang |
collection | PubMed |
description | BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC. METHODS: Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resection-treated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model. RESULTS: There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8 vs. 21.2 months, P=0.048), and similar efficacy was observed between sub-lobectomy and lobectomy/bi-lobectomy patients (OS: 55.6 vs. 30.3 months, P=0.167) in SEER database. At SPH, significantly higher OS was associated with T1 stage (before NAC: T1 vs. T2–4, 48.7 vs. 32.2 months, P=0.025; after NAC: T1 vs. T2–4, 42.7 vs. 21.3 months, P=0.048). Female sex [hazard ratio (HR): 0.078, P=0.009], T1 stage (HR: 13.048, P=0.026), and pneumonectomy (HR: 0.095, P=0.009) were independent prognostic factors for IIIA-SCLC patients who received NAC + intentional radical resection. CONCLUSIONS: For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment. |
format | Online Article Text |
id | pubmed-9459616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-94596162022-09-10 Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis Bian, Dongliang Jiang, Siming Xiong, Yicheng Qi, Mengfan Wu, Jiawei Addeo, Alfredo Yamauchi, Yoshikane Manapov, Farkhad Dempke, Wolfram C. M. Vannucci, Jacopo Di Federico, Alessandro Xu, Xiaoxiong Chen, Linsong Transl Lung Cancer Res Original Article BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC. METHODS: Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resection-treated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model. RESULTS: There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8 vs. 21.2 months, P=0.048), and similar efficacy was observed between sub-lobectomy and lobectomy/bi-lobectomy patients (OS: 55.6 vs. 30.3 months, P=0.167) in SEER database. At SPH, significantly higher OS was associated with T1 stage (before NAC: T1 vs. T2–4, 48.7 vs. 32.2 months, P=0.025; after NAC: T1 vs. T2–4, 42.7 vs. 21.3 months, P=0.048). Female sex [hazard ratio (HR): 0.078, P=0.009], T1 stage (HR: 13.048, P=0.026), and pneumonectomy (HR: 0.095, P=0.009) were independent prognostic factors for IIIA-SCLC patients who received NAC + intentional radical resection. CONCLUSIONS: For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment. AME Publishing Company 2022-08 /pmc/articles/PMC9459616/ /pubmed/36090643 http://dx.doi.org/10.21037/tlcr-22-545 Text en 2022 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Bian, Dongliang Jiang, Siming Xiong, Yicheng Qi, Mengfan Wu, Jiawei Addeo, Alfredo Yamauchi, Yoshikane Manapov, Farkhad Dempke, Wolfram C. M. Vannucci, Jacopo Di Federico, Alessandro Xu, Xiaoxiong Chen, Linsong Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title | Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title_full | Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title_fullStr | Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title_full_unstemmed | Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title_short | Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis |
title_sort | efficacy evaluation of surgery combined with chemotherapy for stage iiia small cell lung cancer patients: a retrospective analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459616/ https://www.ncbi.nlm.nih.gov/pubmed/36090643 http://dx.doi.org/10.21037/tlcr-22-545 |
work_keys_str_mv | AT biandongliang efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT jiangsiming efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT xiongyicheng efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT qimengfan efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT wujiawei efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT addeoalfredo efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT yamauchiyoshikane efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT manapovfarkhad efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT dempkewolframcm efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT vannuccijacopo efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT difedericoalessandro efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT xuxiaoxiong efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis AT chenlinsong efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis |